CD274 and cervical cancer: This antibody is being explored in locally advanced cervical cancer in a randomized phase II trial, the Assessing the Inhibitor PD-L1 Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer (ATEZOLACC) trial (Table 2) (37).